Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Experts Urge More Use Of Evista And Other Drugs To Prevent Breast Cancer

Executive Summary

Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial

You may also be interested in...



Almost At The Phase III Finish Line, Lilly Cuts Arzoxifene Losses

Lilly has decided not to submit the NDA for its osteoporosis drug arzoxifene after Phase III data showed the drug fell short on key secondary outcome measures, the firm announced Aug. 18

Wyeth To Re-Submit Viviant This Year, Expects FDA Advisory Review

Merged Pfizer/Wyeth will likely have to choose between Viviant and Fablyn.

Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along

The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data

Related Content

Topics

UsernamePublicRestriction

Register

PS052160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel